Miles Prince

1.0k total citations
49 papers, 666 citations indexed

About

Miles Prince is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Miles Prince has authored 49 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 22 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Miles Prince's work include Multiple Myeloma Research and Treatments (18 papers), Protein Degradation and Inhibitors (15 papers) and Cutaneous lymphoproliferative disorders research (11 papers). Miles Prince is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Protein Degradation and Inhibitors (15 papers) and Cutaneous lymphoproliferative disorders research (11 papers). Miles Prince collaborates with scholars based in Australia, United States and France. Miles Prince's co-authors include John F. Seymour, Andrew Spencer, Henry Januszewicz, Jerome B. Zeldis, Marta Olesnyckyj, Zhinuan Yu, Robert Knight, Max Wolf, Rodney J. Hicks and Meletios Α. Dimopoulos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The American Journal of Medicine.

In The Last Decade

Miles Prince

48 papers receiving 646 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miles Prince Australia 15 295 268 265 199 95 49 666
S. Vukelja United States 10 179 0.6× 109 0.4× 707 2.7× 67 0.3× 80 0.8× 30 911
Filiz Şen United States 16 112 0.4× 117 0.4× 213 0.8× 278 1.4× 124 1.3× 42 623
Olivier Fitoussi France 13 120 0.4× 162 0.6× 475 1.8× 614 3.1× 123 1.3× 43 870
Claudia Corrado Argentina 14 207 0.7× 206 0.8× 265 1.0× 336 1.7× 35 0.4× 28 661
Antònia Sampol Spain 14 117 0.4× 430 1.6× 189 0.7× 147 0.7× 161 1.7× 60 731
M. L. Vegna Italy 14 517 1.8× 765 2.9× 296 1.1× 186 0.9× 163 1.7× 20 1.2k
Maciej Kaźmierczak Poland 13 161 0.5× 194 0.7× 90 0.3× 102 0.5× 63 0.7× 41 475
Patrizia Lista Italy 12 181 0.6× 325 1.2× 173 0.7× 38 0.2× 252 2.7× 34 735
Pamela Lockbaum United States 9 167 0.6× 208 0.8× 763 2.9× 45 0.2× 93 1.0× 13 983
Dipti Patel‐Donnelly United States 13 130 0.4× 146 0.5× 197 0.7× 216 1.1× 49 0.5× 27 433

Countries citing papers authored by Miles Prince

Since Specialization
Citations

This map shows the geographic impact of Miles Prince's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miles Prince with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miles Prince more than expected).

Fields of papers citing papers by Miles Prince

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miles Prince. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miles Prince. The network helps show where Miles Prince may publish in the future.

Co-authorship network of co-authors of Miles Prince

This figure shows the co-authorship network connecting the top 25 collaborators of Miles Prince. A scholar is included among the top collaborators of Miles Prince based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miles Prince. Miles Prince is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Spruijt, Odette, et al.. (2021). A systematic review on the management of pruritus in patients with cutaneous T-cell lymphoma. Minerva Access (University of Melbourne). 6(2). e55–e55. 4 indexed citations
4.
Quaglino, Pietro, Pablo L. Ortiz‐Romero, M. Bagot, et al.. (2021). Time-to-next-treatment and time-to-next-systemic treatment in patients included in the PROCLIPI registry. European Journal of Cancer. 156. S28–S28. 1 indexed citations
5.
Moreau, Philippe, Gurdeep Parmar, Miles Prince, et al.. (2021). P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21. S152–S153. 1 indexed citations
6.
Blombery, Piers, Ella R. Thompson, Georgina L. Ryland, et al.. (2018). Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. Oncotarget. 9(90). 36126–36136. 57 indexed citations
7.
Gherardin, Nicholas A., Simon J. Harrison, Hang Quach, et al.. (2016). Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. Journal of Translational Medicine. 14(1). 259–259. 16 indexed citations
8.
Shustov, Andrei R., Bertrand Coiffier, Steven M. Horwitz, et al.. (2013). Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials. Blood. 122(21). 4385–4385. 4 indexed citations
9.
Lingaratnam, Senthil, Monica A. Slavin, Bogda Koczwara, et al.. (2011). Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Internal Medicine Journal. 41(1b). 75–81. 29 indexed citations
10.
Lingaratnam, Senthil, Monica A. Slavin, Linda Mileshkin, et al.. (2011). An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Internal Medicine Journal. 41(1b). 110–120. 24 indexed citations
11.
Herbert, Kirsten, Glen Wiesner, Emma Link, et al.. (2010). Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients. Blood. 116(21). 2256–2256. 3 indexed citations
12.
Prince, H. Miles & Miles Prince. (2009). Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma. 3(1). 13 indexed citations
13.
DeAngelo, Daniel J., Andrew Spencer, Thomas Fischer, et al.. (2009). Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.. Blood. 114(22). 2898–2898. 10 indexed citations
14.
Herbert, Kirsten, Jean-Pierre Lévesque, David N. Haylock, & Miles Prince. (2008). The Use of Experimental Murine Models to Assess Novel Agents of Hematopoietic Stem and Progenitor Cell Mobilization. Biology of Blood and Marrow Transplantation. 14(6). 603–621. 8 indexed citations
15.
Piekarz, Richard, James R. Wright, Robin Frye, et al.. (2008). Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).. Blood. 112(11). 1567–1567. 31 indexed citations
16.
17.
Wall, Dominic, Mick Thompson, Linda Mileshkin, et al.. (2005). Tracking Dendritic Cells In Vivo in Patients with Multiple Myeloma.. Blood. 106(11). 3469–3469. 1 indexed citations
18.
19.
Piekarz, Richard, Robin Frye, Maria L. Turner, et al.. (2005). Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.. Blood. 106(11). 231–231. 17 indexed citations
20.
Wirth, Andrew, John F. Seymour, Rodney J. Hicks, et al.. (2002). Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma. The American Journal of Medicine. 112(4). 262–268. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Vukelja Breakdown of academic impact, for papers by Filiz Şen Breakdown of academic impact, for papers by Olivier Fitoussi Breakdown of academic impact, for papers by Claudia Corrado Breakdown of academic impact, for papers by Antònia Sampol Breakdown of academic impact, for papers by M. L. Vegna Breakdown of academic impact, for papers by Maciej Kaźmierczak Breakdown of academic impact, for papers by Patrizia Lista Breakdown of academic impact, for papers by Pamela Lockbaum Breakdown of academic impact, for papers by Dipti Patel‐Donnelly
Rankless by CCL
2026